Baxa releases DoseEdge TPN for automated TPN production

NewsGuard 100/100 Score

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations and increase patient safety, today announced the release of DoseEdge TPN, the industry's first product for completely managing the workflow for automated TPN production. When used with Abacus® TPN calculation software and the ExactaMix™ 2400 Compounder, DoseEdge TPN provides automated support for the entire TPN dose preparation, documentation and inspection process.

"Automated TPN compounding is recognized as one of the most successful pharmacy technologies – adding safety, process control, accuracy and speed to what had been a labor-intensive and error-prone process of compounding TPN doses by hand," notes Larry Gibson, Product Manager. "The Baxa DoseEdge Pharmacy Workflow Manager has supported the safe preparation of more than 1.5 million preparations. DoseEdge TPN leverages this experience – improving the TPN compounding process with complete workflow support and many patient safety enhancements."

After automated TPN compounding is complete, DoseEdge TPN can help catch and prevent errors in the workflow and processes. The software also includes extensive new safety functionality for manual additions. Its pharmacist inspection capabilities, complete dose status tracking – displaying current status and status transitions – and long-term storage of detailed information permit better management and audit of the TPN dose preparation process. Additionally, DoseEdge TPN provides all of the benefits of the company's leading DoseEdge Pharmacy Workflow Manager – including barcode verification of ingredients, automated volume calculations and photographic evidence of proper measurement and injection.

In a prior announcement, Baxa launched significant upgrades to the DoseEdge Pharmacy Workflow Manager. This Baxa DoseEdge Pharmacy Workflow Manager upgrade extends DoseEdge capabilities beyond IV preparation to encompass liquid doses such as oral medications.

SOURCE Baxa Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity showcases cutting-edge solutions at SLAS2024